OBJECTIVE: We evaluated the disease modifying effect of simvastatin and atorvastatin in Dextran Sulfate Sodium (DSS) model of colitis. MATERIALS AND METHODS: Thirty, 8-week old female Swiss-Webster mice were separated into 5 groups (n = 6/group). Colitis was induced by feeding 4 % DSS solution for 7 days. Following discontinuation of DSS, over the next 7 days, the groups orally received simvastatin (20 mg/kg/day), atorvastatin (60 mg/kg/day), vehicle only (0.75 % methylcellulose), subcutaneous 30 mug injections of anti-TNFalpha monoclonal antibody or intraperitoneal anti-mouse apolipoprotein A-I antibody respectively. Disease activity Index (DAI) was determined daily by a blinded investigator. RESULTS: The mean reduction in DAI scores from day 7 to day 14 for anti-TNFalpha group, simvastatin and atorvastatin group were 74 %, 76 % and 64 %, respectively as compared to 41 % reduction in vehicle and anti-apolipoprotein A-I antibody-treated groups. CONCLUSIONS: This finding suggests that statins may have the ability to modify the disease activity in the DSS model of colitis and the disease modifying effect is comparable to anti-mouse TNFalpha treatment in this model.
OBJECTIVE: We evaluated the disease modifying effect of simvastatin and atorvastatin in Dextran Sulfate Sodium (DSS) model of colitis. MATERIALS AND METHODS: Thirty, 8-week old female Swiss-Webster mice were separated into 5 groups (n = 6/group). Colitis was induced by feeding 4 % DSS solution for 7 days. Following discontinuation of DSS, over the next 7 days, the groups orally received simvastatin (20 mg/kg/day), atorvastatin (60 mg/kg/day), vehicle only (0.75 % methylcellulose), subcutaneous 30 mug injections of anti-TNFalpha monoclonal antibody or intraperitoneal anti-mouseapolipoprotein A-I antibody respectively. Disease activity Index (DAI) was determined daily by a blinded investigator. RESULTS: The mean reduction in DAI scores from day 7 to day 14 for anti-TNFalpha group, simvastatin and atorvastatin group were 74 %, 76 % and 64 %, respectively as compared to 41 % reduction in vehicle and anti-apolipoprotein A-I antibody-treated groups. CONCLUSIONS: This finding suggests that statins may have the ability to modify the disease activity in the DSS model of colitis and the disease modifying effect is comparable to anti-mouseTNFalpha treatment in this model.
Authors: K K Gkouskou; M Ioannou; G A Pavlopoulos; K Georgila; A Siganou; G Nikolaidis; D C Kanellis; S Moore; K A Papadakis; D Kardassis; I Iliopoulos; F A McDyer; E Drakos; A G Eliopoulos Journal: Oncogene Date: 2015-08-17 Impact factor: 9.867
Authors: Nadav Slijper; Igor Sukhotnik; Elena Chemodanov; Yulia Bashenko; Ron Shaoul; Arnold G Coran; Jorge Mogilner Journal: Pediatr Surg Int Date: 2010-01 Impact factor: 1.827